BNP/NT-proBNP、sST2与肺动脉高压研究进展

Research progress on the relationship between BNP/NT-proBNP、sST2 and pulmonary arterial hypertension

肺动脉高压(pulmonary arterial hypertension,PAH)是一种由多种原因导致肺动脉压力进行性升高,最终导致右心衰竭甚至死亡的严重心血管疾病。近年来,针对PAH发病机制而研发的多种靶向药物的使用,在一定程度上延缓了该类患者的病情进展,但其远期预后形式仍相当严峻。因此,寻找与病情严重程度密切相关,能对疾病近期及远期预后做出准确预测的生物标记物显得尤为重要。目前为止,血浆脑钠肽(BNP)和N端脑钠肽前体(NT-proBNP)被证明能在相当程度上反应疾病严重程度及评估预后。但可溶性肿瘤抑制体2(sST2),作为新一代心衰生物标记物,被认为能更客观准确地评价疾病严重程度及评估预后。现对BNP/NT-proBNP、sST2与PAH研究进展作简要综述。

Pulmonary arterial hypertension(PAH)is a serious cardiovascular disease that causes progressive elevation of pulmonary artery pressure for a number of reasons, eventually leading to right heart failure and even death.In recent years, the use of targeted drugs developed for the pathogenesis of PAH has delayed the progress of this kind of patients to some extent, but its long-term prognosis is still very severe. Therefore, it is particularly important to find biomarkers which are closely related to the severity of the disease and can accurately predict the short-term and longterm prognosis of the disease. So far, brain natriuretic peptide(BNP)and N-terminal pro-brain natriuretic peptide(NTproBNP) has been proved to reflect the severity and prognosis of the disease to a considerable extent, but soluble suppression of tumorigenicity 2(sST2), as a new generation plasma marker of heart failure, is considered to be more objective and accurate to evaluate the severity and prognosis of the disease. In this paper, the research progress of BNP/NT-proBNP and sST2 in PAH is briefly reviewed.